- Ascendis Pharma press release ( ASND ): Q2 GAAP EPS of -€1.46 beats by €0.69 .
- Revenue of €6.16B (+503.9% Y/Y) beats by €6.15B .
For further details see:
Ascendis Pharma GAAP EPS of -€1.46 beats by €0.69, revenue of €6.16B beats by $6.15BFor further details see:
Ascendis Pharma GAAP EPS of -€1.46 beats by €0.69, revenue of €6.16B beats by $6.15BMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
2024-04-19 17:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 17.87% on an annualized basis producing an average annual retur...
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 44.46% on an annualized basis producing an average annual retur...